4-(4-Pyrrolidin-1-ylphenyl)-2,6-bis(3,4,5-trimethoxyphenyl)pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(4-Pyrrolidin-1-ylphenyl)-2,6-bis(3,4,5-trimethoxyphenyl)pyridine
• 化学式: C₃₃H₃₆N₂O₆
• 分子量: 556.6
• InChiKey: JKRZEIIFEQKLOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  41
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  71.5
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• NOVEL TRISUBSTITUTED PYRIDINE COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1222169A1

  公开（公告）日：2002-07-17
• [EN] NOVEL TRISUBSTITUTED PYRIDINE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES DE PYRIDINE TRISUBSTITUES
  申请人：ASTRAZENECA AB

  公开号：WO2001025204A1

  公开（公告）日：2001-04-12

  The present invention relates to a selective inhibitor of mammalian osteoclast cell activity, processes for its preparation and pharmaceutical compositions comprising the same as well as methods of treatment, where said selective inhibitor is administered to a human or animal patient. Said selective inhibitor has been found to inhibit vacuolar H+-ATPase, such as vacuolar H+-ATPase in osteoclast cells, whereby it is therapeutically efficient against physiological disorders involving bone resorption. In an embodiment of the present invention, said selective inhibitor comprises a trisubstituted pyridine compounds with general formula (I).